Search

The integration of deep learning into clinical decision infrastructure represents a pivotal advancement in healthcare systems and analytics, transforming disparate data streams into actionable intelligence that supports real-time, evidence-based decision-making. This narrative review synthesizes peer-reviewed literature to examine the systems-oriented implications of deep learning deployment within healthcare ecosystems. We focus on the architectural interplay among data ingestion, model inference, and decision-support loops, emphasizing how these elements enable closed-loop systems that adapt to evolving clinical contexts.Deep learning’s capacity to process multimodal data—encompassing electronic health records (EHRs), medical imaging, and real-time monitoring—has enabled sophisticated analytics frameworks that enhance diagnostic accuracy, prognostic modeling, and therapeutic optimization. For instance, fusion techniques combining imaging with structured EHR data have demonstrated potential for precision health applications, enabling nuanced patient stratification and personalized interventions. In mental health, deep learning models applied to outcome research have revealed patterns in longitudinal data, informing system-wide analytics that bridge predictive modeling with clinical workflows.From a systems perspective, the review highlights the evolution of clinical decision support systems (CDSS) augmented by deep learning, which incorporate feedback mechanisms to refine model performance and mitigate risks such as bias amplification. Ethical considerations, including algorithmic fairness and transparency, are integral to sustainable integration, as underscored by guidelines for early-stage evaluation and reporting standards. We explore architectures that facilitate human-AI collaboration, where deep learning serves as an augmentative tool rather than a replacement, ensuring alignment with clinical governance.Challenges in scalability, such as interoperability across healthcare infrastructures and the need for reproducible machine learning pipelines, are critically analyzed through a lens of systems resilience. The synthesis reveals opportunities for closed-loop systems that iteratively learn from interventions, promoting adaptive healthcare delivery. Ultimately, this review posits that deep learning’s role in clinical decision infrastructure hinges on holistic systems design that balances technological innovation with clinical utility and equity. By providing an original interpretive framework, we delineate pathways for integrating deep learning into healthcare analytics and advocate for governance models that prioritize patient-centered outcomes.

Postoperative delirium affects 10–60% of elderly surgical patients and is linked to longer hospital stays, cognitive decline, and increased mortality. Although machine learning models have been developed to predict this condition using perioperative data, most rely on point predictions that fail to express uncertainty, limiting their clinical reliability in high-stakes surgical decision-making. These models often report a single risk estimate without indicating whether predictions are supported by strong or sparse evidence, which can lead to overconfidence and potential patient harm in vulnerable populations with heterogeneous frailty and comorbidity profiles. We argue that Bayesian deep learning is essential for postoperative delirium prediction because it provides distributional outputs and uncertainty estimates that allow clinicians to assess prediction reliability. Incorporating uncertainty quantification can transform these models from opaque tools into clinically trustworthy decision aids. We recommend that uncertainty reporting be required in all predictive models for postoperative delirium and that regulatory and publication standards enforce the use of Bayesian approaches. Overall, replacing point estimates with distributional predictions is necessary to improve safety and clinical utility in perioperative care of elderly patients.

Acute ischemic stroke prediction from electronic health record time series data holds significant potential for enabling early intervention and reducing long-term disability. LSTMs have been widely used to model clinical sequences such as vital signs and laboratory trends, showing strong performance in stroke-related prediction tasks from 2018–2022. However, their sequential nature limits scalability and long-range dependency modeling in large EHR datasets. Transformers, despite transforming sequence modeling in other domains since 2017, remain underused in stroke prediction compared to LSTMs. Although early healthcare studies suggest potential benefits of attention-based models, robust validation in acute ischemic stroke contexts is still limited. Transformers offer advantages in parallel processing, long-range dependency modeling, and interpretability, but require more data and computational resources. They are likely to complement rather than replace LSTMs, with hybrid architectures providing a balanced solution for clinical time series analysis. Key themes include long-range dependency capture, parallel computation, interpretability, and data efficiency trade-offs between LSTMs and transformers. Hybrid LSTM–transformer models may offer improved performance and practicality for stroke prediction, with model selection depending on data scale and clinical constraints. Further benchmarking is needed to determine when transformers or hybrid models outperform LSTMs, guiding the development of more effective stroke prediction systems.

Breast cancer remains a leading cause of cancer-related mortality among women worldwide, underscoring the importance of effective screening strategies for early detection and improved survival. Although conventional modalities such as mammography reduce mortality, they are limited by false positives, false negatives, and overdiagnosis, particularly in dense breast tissue and diverse populations. Deep learning, especially convolutional neural networks (CNNs), has shown promise in improving diagnostic accuracy and reducing inter-reader variability; however, its translation into routine clinical practice requires critical evaluation beyond reported performance metrics. This critical review evaluates CNN-based deep learning applications for breast cancer detection across mammography, ultrasound, and MRI, with emphasis on training strategies and barriers to clinical deployment. A targeted literature search identified peer-reviewed studies focusing on CNN architectures, transfer learning, and implementation challenges. Findings indicate that models such as ResNet, DenseNet, and EfficientNet perform well in controlled settings, supported by transfer learning and data augmentation approaches. However, these results often fail to translate into consistent clinical performance, particularly across imaging modalities and real-world workflows. Limitations including demographic bias, insufficient external validation, and weak evidence of outcome or cost-effectiveness highlight a substantial gap between experimental success and clinical readiness. The review concludes that while deep learning in breast imaging is promising, its adoption should remain cautious and evidence-driven until robust clinical benefit is clearly demonstrated.

Pancreatic cancer is highly lethal, and surgical resection is the only curative option. Preoperative assessment using contrast-enhanced CT is essential for determining tumor resectability based on involvement of key vessels such as the superior mesenteric artery, celiac trunk, and portal vein. Accurate pancreatic tumor segmentation is difficult due to unclear boundaries, low contrast with surrounding tissue, and proximity to major vessels. Manual segmentation is slow, subjective, and inconsistent, especially in borderline cases, while tumor-associated fibrosis further obscures lesion margins. We propose a deep learning-based framework using an attention-enhanced U-Net with multi-scale feature fusion and deep supervision for tumor segmentation and resectability assessment. The model incorporates attention gates, atrous spatial pyramid pooling, and auxiliary losses at multiple decoder levels to improve feature learning and gradient flow. A pre-trained encoder extracts hierarchical features refined by attention mechanisms in skip connections. A multi-scale decoder reconstructs segmentation maps, supported by deep supervision at different resolutions. A parallel branch models tumor–vessel spatial relationships using distance maps to improve resectability classification. This framework enables automated pancreatic tumor segmentation and resectability evaluation from CT scans, improving accuracy, interpretability, and clinical utility. Validation on datasets such as Pancreas-CT and Medical Segmentation Decathlon is recommended.

Oncology drug development is an expensive and high-failure process, with costs exceeding two billion dollars per approved drug and success rates below 10%. Deep learning has recently been explored as a strategy to improve efficiency across the drug discovery pipeline. This systematic review evaluates its application in target identification, compound screening and de novo drug design, and clinical trial optimization. Following PRISMA 2020 guidelines, multiple databases were searched and studies were screened using predefined inclusion criteria, with risk of bias assessed via established tools. The literature shows that graph neural networks and transformer-based models are the most widely used architectures, particularly in early-stage discovery tasks. Although many studies report strong in silico performance, often with AUC values above 0.80, only a small proportion demonstrate experimental or clinical validation. Overall, deep learning significantly advances computational drug discovery in oncology, but translation into clinically validated therapies remains limited, especially in trial optimization, highlighting the need for stronger prospective and experimental validation frameworks.

Sleep disorders, including obstructive sleep apnea, insomnia, restless legs syndrome, narcolepsy, and central sleep apnea, represent a major public health burden. Polysomnography is the diagnostic gold standard but is resource-intensive, leading to increasing use of home sleep apnea testing and wearable devices to improve accessibility. This systematic review evaluates deep learning models in sleep medicine across polysomnography, home sleep apnea testing, and wearable data, focusing on architectures, signal types, validation approaches, diagnostic tasks, and clinical readiness. A PRISMA 2020–compliant search was conducted in PubMed, IEEE Xplore, Scopus, and Web of Science for studies published from 2017 to 2025, including those applying deep learning for sleep staging, apnea/hypopnea detection, or sleep disorder diagnosis using PSG, HSAT, or wearable-derived signals. Twenty-nine studies were included. Convolutional neural networks were the most widely used architecture, often combined with recurrent or hybrid models for temporal dependencies, while transformer-based models have recently emerged for long-sequence sleep analysis. Deep learning methods demonstrate strong performance in sleep staging and respiratory event detection, especially using polysomnography data. However, limited external validation, heterogeneous datasets, and a lack of prospective clinical deployment remain major barriers to clinical translation.

Rare pediatric tumors like sarcomas, neuroblastoma, medulloblastoma, and retinoblastoma pose a challenge for developing deep learning models due to the limited availability of histopathology images, which are distributed across multiple institutions. This scarcity is compounded by privacy concerns, as whole-slide images often contain sensitive clinical and genomic data, and generative adversarial networks (GANs) risk memorizing and leaking training samples. To address this, a differentially private GAN framework is proposed for synthesizing high-resolution histopathology patches of rare pediatric cancers. The framework incorporates a generator for image synthesis, a discriminator for realism assessment, per-sample gradient clipping, Gaussian noise injection, and a privacy accountant, ensuring provable privacy guarantees during the training process. The synthetic images generated can aid in data augmentation, model pre-training, and benchmarking without exposing identifiable pathology data, offering a privacy-preserving solution for dataset augmentation while emphasizing the importance of clinical validation.

Anticoagulation management requires balancing multiple factors such as bleeding risk, thromboembolic risk, drug interactions, and renal function. Deep learning can assist in risk prediction, but its effectiveness relies on clinicians' ability to understand and verify the recommendations. Black-box models may recommend actions without providing clear explanations. In contrast, clinical guidelines are rule-based but not directly executable by neural models. This article introduces a neuro-symbolic XAI framework that combines deep learning predictions with explicit clinical guidelines. It includes a neural prediction module, a symbolic reasoning engine, and an integration layer for traceable justifications. The neuro-symbolic approach connects data-driven predictions to clinical rules, improving auditability and trustworthiness in decision support. This framework aims to enhance anticoagulation management by providing verifiable, clinician-understandable decision support, focusing on explainability-by-design.